CorMedix Inc. has made headlines with its recent announcement of an asset purchase agreement with Heron Therapeutics, valued at $145 million. This strategic move is aimed at expanding CorMedix's portfolio in the pharmaceutical preparations sector, which is critical for its growth and competitiveness.

On November 8, 2026, CorMedix, a Delaware-based pharmaceutical company, entered into this agreement to acquire substantially all of Heron Therapeutics' assets. This acquisition is expected to bolster CorMedix's offerings and enhance its market position.

Background

CorMedix Inc. operates under the SIC code 2834, which categorizes it within the Pharmaceutical Preparations industry. The company trades on the Nasdaq under the ticker symbol CRMD. Recent filings include an 8-K on November 9, 2026, detailing this significant asset purchase agreement.

What the Filing Says

The SEC filing outlines the terms of the asset purchase agreement. CorMedix will issue 14,583,333 shares of its common stock and pay $145 million in cash, subject to adjustments based on Heron's closing cash and net working capital. Additionally, CorMedix will pay royalties on certain product sales and potential earn-out payments based on future sales performance.

Impact

This acquisition could significantly affect CorMedix's competitive standing in the pharmaceutical industry, particularly in areas related to chemotherapy-induced nausea and pain management. The agreement includes provisions for both companies to refrain from soliciting each other's employees for three years, indicating a commitment to stability during the transition.

What's Next

The filing does not specify what happens next, but the completion of this asset sale is contingent upon obtaining stockholder approval from Heron and fulfilling other customary closing conditions.